| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MRPL39 |
| Uniprot No | Q9NYK5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-338 aa |
| 活性数据 | MEALAMGSRA LRLWLVAPGG GIKWRFIATS SASQLSPTEL TEMRNDLFNK EKARQLSLTP RTEKIEVKHV GKTDPGTVFV MNKNISTPYS CAMHLSEWYC RKSILALVDG QPWDMYKPLT KSCEIKFLTF KDCDPGEVNK AYWRSCAMMM GCVIERAFKD EYMVNLVRAP EVPVISGAFC YDVVLDSKLD EWMPTKENLR SFTKDAHALI YKDLPFETLE VEAKVALEIF QHSKYKVDFI EEKASQNPER IVKLHRIGDF IDVSEGPLIP RTSICFQYEV SAVHNLQPTQ PSLIRRFQGV SLPVHLRAHF TIWDKLLERS RKMVTEDQSK ATEECTST |
| 分子量 | 38.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是几篇关于重组人MRPL39蛋白的假设参考文献(基于类似研究的合理推测，可能暂无直接对应文献)：
---
1. **文献名称**：*Recombinant human MRPL39 expression and its role in mitochondrial ribosome assembly*
**作者**：Chen, L. et al. (2020)
**摘要**：本研究成功克隆并表达重组人MRPL39蛋白，利用大肠杆菌系统进行纯化。实验发现MRPL39对线粒体核糖体大亚基的组装至关重要，敲低MRPL39导致线粒体翻译功能受损，提示其在能量代谢中的潜在调控作用。
2. **文献名称**：*MRPL39 overexpression promotes tumor progression via mitochondrial ROS signaling*
**作者**：Wang, Y. et al. (2019)
**摘要**：通过重组MRPL39蛋白功能实验，发现其在肺癌细胞中过表达会增强线粒体活性氧(ROS)的产生，进而激活促癌信号通路。该研究揭示了MRPL39作为癌症治疗潜在靶点的可能性。
3. **文献名称**：*Structural insights into human MRPL39 and its interaction with mitochondrial rRNA*
**作者**：Kim, S. et al. (2021)
**摘要**：通过X射线晶体学解析重组人MRPL39蛋白的三维结构，发现其N端结构域与线粒体16S rRNA特异性结合，为线粒体翻译机制提供了分子层面的解释。
4. **文献名称**：*MRPL39 deficiency leads to impaired oxidative phosphorylation and metabolic syndrome*
**作者**：Gonzalez, R. et al. (2018)
**摘要**：利用重组MRPL29蛋白(注：原文可能为笔误，实为MRPL39)构建体外模型，发现MRPL39缺失导致线粒体复合物Ⅰ活性下降，提示其与代谢综合征的关联性。
---
**说明**：
目前关于MRPL39的研究多集中于基因表达调控与疾病关联，重组蛋白的直接研究较少。若需真实文献，建议在PubMed或Web of Science中以“MRPL39 recombinant”或“MRPL39 mitochondrial ribosome”为关键词检索最新成果。
**Background of Recombinant Human MRPL39 Protein**
MRPL39 (Mitochondrial Ribosomal Protein L39) is a nuclear-encoded component of the mitochondrial ribosome large subunit, essential for mitochondrial protein synthesis. Mitochondria, the cellular powerhouses, rely on their own translation machinery to produce proteins critical for oxidative phosphorylation (OXPHOS), which generates ATP. MRPL39. as part of the 39S large subunit, facilitates the assembly and stability of the mitochondrial ribosome, ensuring proper translation of mitochondrial DNA (mtDNA)-encoded genes.
Structurally, MRPL39 contains conserved domains typical of ribosomal proteins, enabling interactions with rRNA and other ribosomal subunits. Dysfunction in MRPL39 has been linked to mitochondrial disorders, often manifesting as energy-deficient phenotypes such as encephalomyopathy, cardiomyopathy, or metabolic disturbances. Recent studies also suggest potential roles in cancer progression, where altered MRPL39 expression may influence tumor cell metabolism or apoptosis resistance.
Recombinant human MRPL39 protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), enables functional studies, including ribosome assembly analysis, protein-protein interaction assays, and investigations into mitochondrial translation defects. Its availability supports research into mitochondrial diseases, aging, and cancer biology, offering insights into therapeutic targeting of mitochondrial dysfunction.
×
